Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
June 02 2022 - 4:05PM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company seeking to develop innovative proprietary
medicines in areas of significant unmet medical need in oncology
and infectious disease with a current focus on breast cancer and
COVID-19, today announces the appointment of Charles Butler, a
25-year veteran in the healthcare communications space, as vice
president of investor relations and public relations.
“As Atossa continues to develop our pipeline both in breast
cancer and COVID-19, the necessity for an in-house strategic
manager for our communications has become an important priority and
Charles’s extensive experience within the industry as a liaison for
both investors and the media make him a valuable asset,” commented
Dr. Steven Quay, Atossa’s President and Chief Executive
Officer.
Prior to joining Atossa, Mr. Butler spent 10 years at Exelixis,
Inc. where he managed all communications from the preclinical
through commercial stage for multiple drugs. During his time at
Exelixis, he was a part of the team that raised over $1B in equity
and business development transactions. Prior to Exelixis, he worked
at Ogilvy in New York and London. At Ogilvy he was part of the team
that launched multiple blockbuster drugs for several pharmaceutical
companies including Merck and Pfizer. While in London, he managed a
25+ person team, overseeing healthcare communications for the
United Kingdom and Europe. He has also worked at Castlight Health,
ICR, Adverum, Eiger Biopharmaceuticals and IN8bio, Inc.
Mr. Butler graduated from George Washington University with a
B.A. in Political Science.
“The unique opportunity to be part of the Atossa team that is
working to bring new products to market in breast cancer and other
important diseases is exciting. It will allow me to leverage my
many years of experience across the communications spectrum in
biotechnology. I look forward to collaborating closely with
management to ensure its strong message of innovation and patient
care are clearly received in this crowded marketplace,” added Mr.
Butler.
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to develop innovative proprietary medicines in
areas of significant unmet medical need in oncology and infectious
diseases with a current focus on breast cancer and COVID-19. For
more information, please visit
www.atossatherapeutics.com.
FORWARD-LOOKING STATEMENTS DISCLAIMER STATEMENT
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including,
without limitation, statements regarding the satisfaction of
closing conditions relating to the offering and the anticipated use
of proceeds from the offering, the risks and uncertainties
associated with any variation between interim and final clinical
results, actions and inactions by the FDA, the outcome or timing of
regulatory approvals needed by Atossa including those needed to
commence and continue studies of AT-H201, AT-301 and Endoxifen,
lower than anticipated rate of patient enrollment, estimated market
size of drugs under development, the safety and efficacy of
Atossa’s products, performance of clinical research organizations
and investigators, obstacles resulting from proprietary rights held
by others such as patent rights, whether reduction in Ki-67 or any
other result from a neoadjuvant study or reduction of breast
density will be approvable endpoints for oral Endoxifen, and other
risks detailed from time to time in Atossa’s filings with the
Securities and Exchange Commission, including without limitation
its periodic reports on Form 10-K and 10-Q, each as amended and
supplemented from time to time.
COMPANY CONTACT:
Atossa Therapeutics, Inc.Kyle Guse, CFO and General
CounselOffice: (866) 893-4927kyle.guse@atossainc.com
INVESTOR RELATIONS CONTACT:Core IROffice: (516)
222-2560ir@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024